Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine (Innocoll)
- Development stage
- Approved
- Lead developer
- Innocoll
- Modality
- Small Molecules
- Administration
- Implant
01
Overview
Bupivacaine collagen sponge, marketed under the brand name XaraColl, is a drug-device combination product developed by Innocoll for the management of postoperative pain. It consists of a biodegradable and fully bioresorbable collagen matrix derived from bovine tendon, impregnated with the local anesthetic bupivacaine hydrochloride. Utilizing Innocoll's proprietary CollaRx technology, the implant is placed directly into the surgical site during closure, where it provides sustained release of bupivacaine for up to 96 hours. Bupivacaine acts by blocking voltage-gated sodium channels, thereby inhibiting nerve conduction and providing localized analgesia. The collagen matrix also provides hemostatic properties and supports the natural wound-healing process. It was FDA-approved in 2020 for use in adults following open inguinal hernia repair.
- Brand names
- XaraColl
- Other names
- bupivacaine collagen spongeCollaRx Bupivacaine Implantbupivacaine hydrochloride collagen-matrix implant
02
Targets
KCNK5 (Potassium channel subfamily K member 5)SCN5A (Sodium channel protein type 5 subunit alpha)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on bupivacaine (Innocoll).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine (Innocoll).